KRAS and colorectal carcinoma: Having ascertained that PRMT5 is further overexpressed at both the translational and transcriptional levels in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells, a cell viability assay was then carried out to determine whether this further overexpression of PRMT5 in the KRAS mutant CRC cells has clinical applicability.